Literature DB >> 21423813

Extracellular Regulation of Myostatin: A Molecular Rheostat for Muscle Mass.

Se-Jin Lee1.   

Abstract

Myostatin (MSTN) is a transforming growth factor-ß family member that plays a critical role in regulating skeletal muscle mass. Genetic studies in multiple species have demonstrated that mutations in the Mstn gene lead to dramatic and widespread increases in muscle mass as a result of a combination of increased fiber numbers and increased fiber sizes. MSTN inhibitors have also been shown to cause significant increases in muscle growth when administered to adult mice. As a result, there has been an extensive effort to understand the mechanisms underlying MSTN regulation and activity with the goal of developing the most effective strategies for targeting this signaling pathway for clinical applications. Here, I review the current state of knowledge regarding the regulation of MSTN extracellularly by binding proteins and discuss the implications of these findings both with respect to the fundamental physiological role that MSTN plays in regulating tissue homeostasis and with respect to the development of therapeutic agents to combat muscle loss.

Entities:  

Year:  2010        PMID: 21423813      PMCID: PMC3060380          DOI: 10.2174/187152210793663748

Source DB:  PubMed          Journal:  Immunol Endocr Metab Agents Med Chem        ISSN: 1871-5222


  92 in total

1.  Difference between follistatin isoforms in the inhibition of activin signalling: activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin.

Authors:  O Hashimoto; N Kawasaki; K Tsuchida; S Shimasaki; T Hayakawa; H Sugino
Journal:  Cell Signal       Date:  2000-08       Impact factor: 4.315

2.  The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding.

Authors:  Thomas B Thompson; Thomas F Lerch; Robert W Cook; Teresa K Woodruff; Theodore S Jardetzky
Journal:  Dev Cell       Date:  2005-10       Impact factor: 12.270

3.  Molecular definition of an allelic series of mutations disrupting the myostatin function and causing double-muscling in cattle.

Authors:  L Grobet; D Poncelet; L J Royo; B Brouwers; D Pirottin; C Michaux; F Ménissier; M Zanotti; S Dunner; M Georges
Journal:  Mamm Genome       Date:  1998-03       Impact factor: 2.957

4.  The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-4.

Authors:  A Fainsod; K Deissler; R Yelin; K Marom; M Epstein; G Pillemer; H Steinbeisser; M Blum
Journal:  Mech Dev       Date:  1997-04       Impact factor: 1.882

5.  Myostatin propeptide-mediated amelioration of dystrophic pathophysiology.

Authors:  Sasha Bogdanovich; Kelly J Perkins; Thomas O B Krag; Lisa-Anne Whittemore; Tejvir S Khurana
Journal:  FASEB J       Date:  2005-04       Impact factor: 5.191

6.  Expression of myostatin pro domain results in muscular transgenic mice.

Authors:  J Yang; T Ratovitski; J P Brady; M B Solomon; K D Wells; R J Wall
Journal:  Mol Reprod Dev       Date:  2001-11       Impact factor: 2.609

7.  Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

Authors:  Ferrill F Rose; Virginia B Mattis; Hansjörg Rindt; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2008-12-12       Impact factor: 6.150

8.  Titin-cap associates with, and regulates secretion of, Myostatin.

Authors:  Gina Nicholas; Mark Thomas; Brett Langley; Wayne Somers; Ketan Patel; C Fred Kemp; Mridula Sharma; Ravi Kambadur
Journal:  J Cell Physiol       Date:  2002-10       Impact factor: 6.384

9.  Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases.

Authors:  Neil M Wolfman; Alexandra C McPherron; William N Pappano; Monique V Davies; Kening Song; Kathleen N Tomkinson; Jill F Wright; Liz Zhao; Suzanne M Sebald; Daniel S Greenspan; Se-Jin Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-11       Impact factor: 11.205

10.  Adeno-associated virus-8-mediated intravenous transfer of myostatin propeptide leads to systemic functional improvements of slow but not fast muscle.

Authors:  Keith Foster; Ian R Graham; Anthony Otto; Helen Foster; Capucine Trollet; Paul J Yaworsky; Frank S Walsh; Dale Bickham; Nancy A Curtin; Susannah L Kawar; Ketan Patel; George Dickson
Journal:  Rejuvenation Res       Date:  2009-04       Impact factor: 4.663

View more
  41 in total

1.  GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration.

Authors:  Marc A Egerman; Samuel M Cadena; Jason A Gilbert; Angelika Meyer; Hallie N Nelson; Susanne E Swalley; Carolyn Mallozzi; Carsten Jacobi; Lori L Jennings; Ieuan Clay; Gaëlle Laurent; Shenglin Ma; Sophie Brachat; Estelle Lach-Trifilieff; Tea Shavlakadze; Anne-Ulrike Trendelenburg; Andrew S Brack; David J Glass
Journal:  Cell Metab       Date:  2015-05-19       Impact factor: 27.287

2.  Prostate tumor-derived GDF11 accelerates androgen deprivation therapy-induced sarcopenia.

Authors:  Chunliu Pan; Neha Jaiswal Agrawal; Yanni Zulia; Shalini Singh; Kai Sha; James L Mohler; Kevin H Eng; Joe V Chakkalakal; John J Krolewski; Kent L Nastiuk
Journal:  JCI Insight       Date:  2020-03-26

3.  Sparing of muscle mass and function by passive loading in an experimental intensive care unit model.

Authors:  Guillaume Renaud; Monica Llano-Diez; Barbara Ravara; Luisa Gorza; Han-Zhong Feng; Jian-Ping Jin; Nicola Cacciani; Ann-Marie Gustafson; Julien Ochala; Rebeca Corpeno; Meishan Li; Yvette Hedström; G Charles Ford; K Sreekumaran Nair; Lars Larsson
Journal:  J Physiol       Date:  2012-12-24       Impact factor: 5.182

4.  Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Chandramohan Kattamuri; Kristof Nolan; Huaying Zhao; Yisrael Sidis; Henry T Keutmann; Thomas B Thompson
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

5.  Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation.

Authors:  Qian Wang; Alexandra C McPherron
Journal:  J Physiol       Date:  2012-03-05       Impact factor: 5.182

Review 6.  The molecular basis for load-induced skeletal muscle hypertrophy.

Authors:  George R Marcotte; Daniel W D West; Keith Baar
Journal:  Calcif Tissue Int       Date:  2014-10-31       Impact factor: 4.333

7.  Soluble activin receptor type IIB treatment does not cause fat loss in mice with diet-induced obesity.

Authors:  A C McPherron; T Guo; Q Wang; J Portas
Journal:  Diabetes Obes Metab       Date:  2011-11-21       Impact factor: 6.577

Review 8.  Disease drivers of aging.

Authors:  Richard J Hodes; Felipe Sierra; Steven N Austad; Elissa Epel; Gretchen N Neigh; Kristine M Erlandson; Marissa J Schafer; Nathan K LeBrasseur; Christopher Wiley; Judith Campisi; Mary E Sehl; Rosario Scalia; Satoru Eguchi; Balakuntalam S Kasinath; Jeffrey B Halter; Harvey Jay Cohen; Wendy Demark-Wahnefried; Tim A Ahles; Nir Barzilai; Arti Hurria; Peter W Hunt
Journal:  Ann N Y Acad Sci       Date:  2016-12       Impact factor: 5.691

9.  TGFβ Superfamily Members Mediate Androgen Deprivation Therapy-Induced Obese Frailty in Male Mice.

Authors:  Chunliu Pan; Shalini Singh; Deepak M Sahasrabudhe; Joe V Chakkalakal; John J Krolewski; Kent L Nastiuk
Journal:  Endocrinology       Date:  2016-09-09       Impact factor: 4.736

10.  Acute resistance exercise activates rapamycin-sensitive and -insensitive mechanisms that control translational activity and capacity in skeletal muscle.

Authors:  Daniel W D West; Leslie M Baehr; George R Marcotte; Courtney M Chason; Luis Tolento; Aldrin V Gomes; Sue C Bodine; Keith Baar
Journal:  J Physiol       Date:  2015-12-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.